Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Generic

Thumbnail
September 26, 2019

How Labour’s UK generic drugs plan could have been better

Companies and investors have not completely dismissed the UK Labour party’s proposals for cheaper drugs – but some ideas have proven more equal than others.

Thumbnail
May 14, 2019

Price fixing case caps a terrible week for generics

Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector. 

Article image
Vantage logo
January 31, 2019

Mylan makes for a piece of the shrinking Advair pie

Article image
Vantage logo
October 31, 2018

Samsung joins Soliris biosimilar quest

Article image
Vantage logo
September 07, 2018

Civica Rx goes where generics companies fear to tread

A non-profit partnership of 500 hospitals wants to deliver its first generic drugs in 2019, lowering prices and stabilising supplies.

Article image
Vantage logo
August 17, 2018

With Epipen Teva investors have something to celebrate at last

Vantage logo
May 15, 2018

Pfenex readies to swim upstream with Forteo copycat

Vantage logo
May 03, 2018

Biosimilar knockbacks expose increasing big pharma focus

Vantage logo
April 17, 2018

Private equity cleans up Sanofi’s failed generics foray

Vantage logo
February 20, 2018

Interview – Rani’s pill injector promises much, but is still preclinical

Vantage logo
January 24, 2018

Novartis investors put faith in new chief

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.